Solvonis Therapeutics plc
LSE: SVNS.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Industrials
- Industry
- Industrial - Machinery
- CEO
- Anthony James Tennyson
- Employees
- 3
- Headquarters
- London, United Kingdom
- IPO year
- 2022
- Market cap
- £16.3M
- Website
- https://www.graftpolymer.com
Loading SVNS…
Loading profile data…Frequently asked questions about SVNS
What does Solvonis Therapeutics plc (SVNS.L) do?
Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer...
Where does SVNS.L trade?
Solvonis Therapeutics plc (SVNS.L) trades on the London Stock Exchange.
What sector is SVNS.L in?
Solvonis Therapeutics plc (SVNS.L) operates in the Industrials sector, specifically in the Industrial - Machinery industry.
Who is the CEO of Solvonis Therapeutics plc?
Anthony James Tennyson is the chief executive officer of Solvonis Therapeutics plc (SVNS.L).
Where is Solvonis Therapeutics plc headquartered?
Solvonis Therapeutics plc is headquartered in United Kingdom.
Does SVNS.L pay a dividend?
Solvonis Therapeutics plc (SVNS.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SVNS.L go public?
Solvonis Therapeutics plc (SVNS.L) completed its initial public offering in 2022.